Immunovant
Developing imeroprubart across six IgG-driven autoimmune diseases.
$40.58
After-hours close−0.61 (−1.48%)
At close$41.19(−6.00%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 55.48%Insiders 57.05%
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 206.40M · Float 79.36M · 38.5% free float
Institutions13F, as of Jun 30, 2026
239 holders · 114.51M shares · 41 new positions · 114 increased · 81 reduced · 27 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 16.19M | 7.84% | −761.4K | Aug 13, 2026 |
| Deep Track Capital, LP | 9.34M | 4.53% | −2.19M | Aug 14, 2026 |
| BlackRock, Inc. | 7.18M | 3.48% | +606.4K | Aug 7, 2026 |
| Farallon Capital Management LLC | 5.81M | 2.81% | +4.26M | Aug 14, 2026 |
| Baker Bros. Advisors LP | 5.44M | 2.63% | −22.7K | Aug 14, 2026 |
| State Street Corp | 4.62M | 2.24% | +79.1K | Aug 7, 2026 |
| Morgan Stanley | 4.53M | 2.20% | +658.0K | Aug 13, 2026 |
| TCG Crossover Management, LLC | 4.46M | 2.16% | 0 | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 55.90% | 113.33M | 13D | Dec 12, 2025 ↗ |
| FMR LLC | 8.40% | 14.73M | 13G | Nov 5, 2025 ↗ |
| Deep Track Capital, LP | 5.59% | 9.50M | 13G | Mar 26, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Roivant Sciences Ltd. | director, 10 percent owner: | 113.32M | 54.90% | Dec 12, 2025 |
| Peter Salzmann | director, officer: Chief Executive Officer | 1.18M | 0.57% | Apr 17, 2025 |
| Frank Torti | director | 1.01M | 0.49% | Apr 9, 2026 |
| Eva Renee Barnett | officer: Chief Financial Officer | 396.8K | 0.19% | Apr 17, 2025 |
| Eric Venker | director, officer: Chief Executive Officer | 254.3K | 0.12% | Jul 6, 2026 |
| Tiago Girao | officer: Chief Financial Officer | 240.8K | 0.12% | Jul 24, 2026 |
| Melanie Gloria | officer: Chief Operating Officer | 219.3K | 0.11% | Aug 21, 2026 |
| Michael Geffner | officer: Chief Medical Officer | 218.0K | 0.11% | Oct 24, 2025 |
| Jay S. Stout | officer: Chief Technology Officer | 205.3K | 0.10% | Jul 24, 2026 |
| Christopher van Tuyl | officer: Chief Legal Officer | 179.4K | 0.09% | Jul 10, 2026 |
1 ten-percent owner holds 2.88M shares by Form 4 — the 13D/G table above shows that stake, the figure above counts officers and directors only · 11 people have not refiled in the last 18 months (2.36M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 28, 2026 | Atul Pandedirector | Sale | 1,500 | $43.27 | 116,731 |
| Aug 20, 2026 | Melanie Gloriaofficer: Chief Operating Officer | Sale | 3,056 | $44.16 | 219,301 |
| Jul 23, 2026 | Jay S. Stoutofficer: Chief Technology Officer | Sale | 2,857 | $38.69 | 205,341 |
| Jul 23, 2026 | Tiago Giraoofficer: Chief Financial Officer | Sale | 6,798 | $38.69 | 240,798 |
| Jul 24, 2026 | Atul Pandedirector | Sale | 1,500 | $39.80 | 116,731 |
| Jul 8, 2026 | Jay S. Stoutofficer: Chief Technology Officer | Sale · 4 lots | 3,487 | $39.55 | 208,198 |
| Jul 8, 2026 | Christopher van Tuylofficer: Chief Legal Officer | Sale · 2 lots | 1,206 | $39.55 | 179,391 |
| Jul 8, 2026 | Melanie Gloriaofficer: Chief Operating Officer | Sale · 2 lots | 2,036 | $39.55 | 222,357 |
| Jul 2, 2026 | Eric Venkerdirector, officer: Chief Executive Officer | Sale | 3,092 | $38.48 | 254,280 |
| Jun 26, 2026 | Atul Pandedirector | Sale | 1,500 | $38.01 | 116,731 |
CongressHouse and Senate disclosures
Not reported.